Literature DB >> 10446497

Comparison of leukopenia between cytarabine and behenoyl cytarabine in JALSG AML-89 consolidation therapy. The Japan Adult Leukemia Study Group.

S Miyawaki, T Kobayashi, M Tanimoto, K Kuriyama, H Murakami, M Yoshida, S Minami, K Minato, K Tsubaki, E Omoto, H Oh, I Jinnai, H Sakamaki, A Hiraoka, A Kanamaru, I Takahashi, K Saito, T Naoe, O Yamada, N Asou, S Kageyama, N Emi, T Ueda, M Tomonaga, R Ohno.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10446497

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  4 in total

1.  Expression of myeloperoxidase and gene mutations in AML patients with normal karyotype: double CEBPA mutations are associated with high percentage of MPO positivity in leukemic blasts.

Authors:  Shinya Tominaga-Sato; Hideki Tsushima; Koji Ando; Hidehiro Itonaga; Yoshitaka Imaizumi; Daisuke Imanishi; Masako Iwanaga; Jun Taguchi; Takuya Fukushima; Shinichiro Yoshida; Tomoko Hata; Yukiyoshi Moriuchi; Kazutaka Kuriyama; Hiroyuki Mano; Masao Tomonaga; Yasushi Miyazaki
Journal:  Int J Hematol       Date:  2011-06-16       Impact factor: 2.490

2.  Randomized comparison of fixed-schedule versus response-oriented individualized induction therapy and use of ubenimex during and after consolidation therapy for elderly patients with acute myeloid leukemia: the JALSG GML200 Study.

Authors:  Atsushi Wakita; Shigeki Ohtake; Satoru Takada; Fumiharu Yagasaki; Hirokazu Komatsu; Yasushi Miyazaki; Kohmei Kubo; Yukihiko Kimura; Akihiro Takeshita; Yoko Adachi; Hitoshi Kiyoi; Takuhiro Yamaguchi; Minoru Yoshida; Kazunori Ohnishi; Shuichi Miyawaki; Tomoki Naoe; Ryuzo Ueda; Ryuzo Ohno
Journal:  Int J Hematol       Date:  2012-05-26       Impact factor: 2.490

3.  Close correlation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate, an intracellular active metabolite, to the therapeutic efficacy of N(4)-behenoyl-1-beta-D-arabinofuranosylcytosine therapy for acute myelogenous leukemia.

Authors:  T Yamauchi; Y Kawai; N Goto; S Kishi; S Imamura; A Yoshida; Y Urasaki; T Fukushima; H Iwasaki; H Tsutani; M Masada; T Ueda
Journal:  Jpn J Cancer Res       Date:  2001-09

4.  Idarubicin plus behenoyl cytarabine and 6-thioguanine compares favorably with idarubicin plus cytarabine-based regimen for children with previously untreated acute myeloid leukemia: 10-year retrospective, multicenter study in Korea.

Authors:  Dae Hyoung Lee; Nak Gyun Chung; Bin Cho; Hack Ki Kim; Hyoung Jin Kang; Hee Young Shin; Hyo Seop Ahn; Keon Hee Yoo; Ki Woong Sung; Hong Hoe Koo; Hoon Kook; Tai Ju Hwang; Ho Joon Im; Jong Jin Seo; Hyeon Jin Park
Journal:  J Korean Med Sci       Date:  2009-12-26       Impact factor: 2.153
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.